Why the study?
Does baseline serum adiponectin level predict the progression of carotid atherosclerosis in patients with type 2 diabetes mellitus?
Does baseline serum adiponectin level predict the progression of carotid atherosclerosis in patients with type 2 diabetes mellitus?
Baseline serum adiponectin levels do not significantly predict the 1-year progression of carotid intima-media thickness in patients with type 2 diabetes, whereas HbA1c remains an independent predictor.
Baseline adiponectin does not predict 1-year CIMT progression in T2DM; leaves open its role in longer-term atherosclerosis risk.
Background: Increased cardiovascular events, which is the leading cause of death in type 2 diabetic patients, are mainly caused by accelerated atherosclerosis. Adiponectin has been suggested as a risk factor for cardiovascular diseases in cross-sectional studies. However, little is known about the impact of adiponectin on the progression of carotid atherosclerosis in type 2 diabetic patients. This study was conducted to evaluate the impact of early adiponectin levels on the progression of carotid atherosclerosis. Methods: From March 2009, 150 patients with type 2 diabetes were consecutively enrolled in our affiliated outpatient clinic. Anthropometric and biochemical data, including adiponectin levels, were measured in each participant. We measured the carotid intima-media thickness (CIMT) at baseline and at 1-year follow-up (n = 111). Then, we prospectively studied the relationship between the serum adiponectin levels and the progression of CIMT for 1 year. Results: Adiponectin levels negatively correlated with CIMT (r = -0.219, P = 0.015). Moreover, mean progression of CIMT was 0.016 0.040 mm. However, there was no correlation between adiponectin levels and the progression of CIMT within 1-year follow-up period (r = -0.156, P = 0.080). Age ( = 0.556, P = 0.004), LDL cholesterol ( = 0.276, P = 0.042), and A1C ( = 0.309, P = 0.038) were found to be independent risk factors for CIMT. However, A1C ( = 0.311, P = 0.042) was found to be the only independent risk factor for the progression of CIMT.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: